MEDFF - MedReleaf Corp.

Other OTC - Other OTC Delayed Price. Currency in USD
20.90
+0.11 (+0.53%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close20.79
Open20.75
Bid0.00 x 0
Ask0.00 x 0
Day's Range20.36 - 21.32
52 Week Range5.86 - 24.99
Volume89,484
Avg. Volume166,842
Market Cap2.155B
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-0.06
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • ACCESSWIRE9 days ago

    Today's Research Reports on Trending Tickers: Canopy Growth and MedReleaf

    NEW YORK, NY / ACCESSWIRE / July 9, 2018 / U.S. equities posted solid gains on Friday, ending the week on a positive note, supported by a stronger-than-expected jobs report. The Dow Jones Industrial Average ...

  • CNW Group12 days ago

    Aurora Cannabis Receives Competition Bureau Clearance for MedReleaf Acquisition

    Aurora Cannabis Receives Competition Bureau Clearance for MedReleaf Acquisition

  • TheStreet.com14 days ago

    How to Invest in Cannabis - In Its Many Forms

    When states and countries legalize cannabis, new businesses appear out of nowhere. California legalized recreational marijuana at the very beginning of 2018. Within two weeks, two dozen Los Angeles businesses got approval to sell recreational products.

  • ACCESSWIRE26 days ago

    Today's Research Reports on Trending Tickers: MedReleaf and Aurora Cannabis

    NEW YORK, NY / ACCESSWIRE / June 22, 2018 / Major U.S. markets closed down on Thursday, with the Dow Jones posting its 8th consecutive daily decline, as investors' attention remained fixed on trade tension ...

  • InvestorPlacelast month

    Marijuana ETFs Are the Smart Way to Play Canada’s Cannabis Market

    Canopy Growth Corp (NYSE:CGC), the second Canadian pure-play marijuana stock, hit U.S. markets May 24. American investors now have direct access to two of the biggest players in the global cannabis market. There are a number of different ways investors can put their hard-earned dollars to work in what is arguably one of the fastest growing industries in the world, but the easiest is to buy one of the several marijuana ETFs available.

  • 4 Marijuana Stocks I Wouldn't Buy
    Motley Foollast month

    4 Marijuana Stocks I Wouldn't Buy

    Despite their strong growth potential, the buzz surrounding these four pot stocks is a bit too much.

  • ACCESSWIRElast month

    Today's Research Reports on Trending Tickers: Aurora Cannabis and MedReleaf Corp.

    NEW YORK, NY / ACCESSWIRE / June 6, 2018 / Major indexes closed mostly higher Tuesday, lifted by a rally from the technology sector. The Dow Jones Industrial Average decreased 0.06 percent to close at ...

  • Motley Fool2 months ago

    Aurora Cannabis: 3 Reasons to Buy, 3 Reasons to Sell

    This Canadian weed kingpin is up nearly 1,700% on a trailing-two-year basis, but does it still have room to run?

  • CNW Group2 months ago

    Aurora Cannabis and MedReleaf File Arrangement Agreement and Material Change Reports

    EDMONTON and MARKHAM, ON , May 25, 2018 /CNW/ - Aurora Cannabis Inc. ("Aurora") (ACB.TO) and MedReleaf Corp. ("MedReleaf") (LEAF.TO) today announced the filing on SEDAR of the arrangement agreement dated May 14, 2018 between Aurora and MedReleaf (the "Original Agreement"), as amended by an amending agreement (the "Amending Agreement"), and the material change reports in respect of the previously announced transaction whereby Aurora intends to acquire all of the issued and outstanding common shares of MedReleaf (the "Material Change Reports"). Aurora and MedReleaf have agreed to amend the Original Agreement to include, in the consideration payable to holders of MedReleaf's common shares, (each a "MedReleaf Share"), $0.000001 in cash for each MedReleaf Share. As a result, the consideration under the arrangement has been increased from 3.575 Aurora common shares for each MedReleaf Share to 3.575 Aurora common shares and $0.000001 in cash for each MedReleaf Share.  Taxable Canadian resident MedReleaf shareholders will be entitled to elect to receive tax-deferred roll-over treatment in connection with the acquisition by Aurora of their MedReleaf Shares.  If a MedReleaf shareholder does not, or is unable to, make an election, then Aurora's acquisition cost for such shareholder's MedReleaf Shares will generally be equal to the fair market value of such shares.

  • Aurora Cannabis Stock Rises 5.8% on Investment in CTT
    Market Realist2 months ago

    Aurora Cannabis Stock Rises 5.8% on Investment in CTT

    On May 22, Aurora Cannabis (ACB) (ACBFF) added yet another name to its long list of partnerships ahead of legalized cannabis in Canada. The company acquired a 9.1% ownership interest in CTT Pharmaceutical Holdings through a private placement. This deal further has a provision for Aurora Cannabis to increase its stake to 42.5% in CTT.

  • Investors Should Avoid Aurora Cannabis' Acquisition of MedReleaf Like the Plague
    Motley Fool2 months ago

    Investors Should Avoid Aurora Cannabis' Acquisition of MedReleaf Like the Plague

    This is a deal where both sides could actually lose.

  • Why Analysts Are Loving Cannabis Stocks in May
    Market Realist2 months ago

    Why Analysts Are Loving Cannabis Stocks in May

    With the anticipation of huge demand for cannabis, which translates into potential earnings growth, analysts are quite bullish on cannabis stocks in May. Most companies have seen increased bullishness over the last month, as we’ll discuss in this series. On May 15, Canopy Growth (WEED) stock was in the news again for its latest agreement to acquire Canopy Health Innovation and its subsidiary, Canopy Animal Health.

  • Cronos Group Stock Falls ~5% after Q1 Earnings Release
    Market Realist2 months ago

    Cronos Group Stock Falls ~5% after Q1 Earnings Release

    Cronos Group (CRON) reported its first-quarter earnings on May 15. The company’s sales rose almost 4.8 times year-over-year to 2.9 million Canadian dollars from 0.5 million Canadian dollars in the first quarter of 2017. Sequentially, sales grew 83% from 1.3 million Canadian dollars.

  • 3 Reasons the Market Yawned at the Biggest Marijuana Stock Deal in History
    Motley Fool2 months ago

    3 Reasons the Market Yawned at the Biggest Marijuana Stock Deal in History

    Aurora Cannabis is buying MedReleaf in the biggest marijuana acquisition ever. But here's why investors aren't overly excited.

  • Canopy Growth Stock Surged over 7% on NYSE Listing Announcement
    Market Realist2 months ago

    Canopy Growth Stock Surged over 7% on NYSE Listing Announcement

    Today, Canopy Growth (WEED) stock surged more than 7% on news of its application to list its common shares on the NYSE (New York Stock Exchange). This news comes on the heels of Aurora Cannabis (ACB)(ACBFF) announcing its acquisition of MedReleaf (MEDFF) today. Read more in MedReleaf Stock Rises on Aurora Cannabis Acquisition.

  • MedReleaf Stock Rises on Aurora Cannabis Acquisition
    Market Realist2 months ago

    MedReleaf Stock Rises on Aurora Cannabis Acquisition

    Today, Aurora Cannabis (ACB)(ACBFF) announced that it agreed to acquire all of MedReleaf’s (MEDFF) outstanding common shares for about 3.2 billion Canadian dollars. On the other hand, Aurora Cannabis stock fell almost 2.5% to 7.9 Canadian dollars. According to Aurora Cannabis’s press release, the acquisition price of 29.4 Canadian dollars implies a premium of 34% over both companies’ 20-day VWAP (volume-weighted average price) common shares as of May 11.

  • Reefer Merger Madness: Aurora Cannabis, MedReleaf In Record Deal; Canopy Growth Plans NYSE Listing
    Investor's Business Daily2 months ago

    Reefer Merger Madness: Aurora Cannabis, MedReleaf In Record Deal; Canopy Growth Plans NYSE Listing

    Aurora Cannabis on Monday agreed to buy fellow Canadian pot stock MedReleaf for $2.5 billion, a record industry deal. Canada's Canopy Growth plans a NYSE listing.

  • How Cannabis Stocks Performed Last Week
    Market Realist2 months ago

    How Cannabis Stocks Performed Last Week

    Strong sentiment in the cannabis sector pushed ETFs and stocks into positive territory last week. The Horizons Marijuana Life Sciences ETF (HMMJ) closed 4.4% higher, while its US-listed counterpart, the Horizons Marijuana Life Sciences Index ETF (HMLSF), rose 4.8%. Similarly, the Emerging Marijuana Growers Index ETF (HMJR) rose 4.3%, and the Evolve Marijuana ETD (SEED) rose 2.5% between its close on May 4 and its close on May 11.

  • Better Marijuana Stock: MedReleaf vs. Cronos Group
    Motley Fool2 months ago

    Better Marijuana Stock: MedReleaf vs. Cronos Group

    They're two of the biggest Canadian marijuana stocks on the market, but which is the better pick for investors?

  • CNW Group2 months ago

    Media Advisory - A Special Announcement from Aurora Cannabis and MedReleaf

    Media Advisory - A Special Announcement from Aurora Cannabis and MedReleaf

  • CNW Group2 months ago

    Aurora Cannabis to Acquire MedReleaf

    EDMONTON and MARKHAM, ON , May 14, 2018 /CNW/ - Aurora Cannabis Inc. ("Aurora") (ACB.TO) and MedReleaf Corp. ("MedReleaf") (LEAF.TO) are pleased to announce that they have entered into a definitive arrangement agreement (the "Arrangement Agreement") whereby Aurora intends to acquire all of the issued and outstanding common shares of MedReleaf in an all-share transaction valued at approximately C$3.2 billion on a fully diluted basis (the "Transaction"). Under the terms of the Arrangement Agreement, holders of MedReleaf common shares will receive 3.575 common shares of Aurora for each MedReleaf common share held (the "Exchange Ratio").

  • This Marijuana Stock Acquisition Would Make a Lot of Sense -- and Dollars, Too
    Motley Fool2 months ago

    This Marijuana Stock Acquisition Would Make a Lot of Sense -- and Dollars, Too

    Could a potential combination of Aurora Cannabis and MedReleaf lead to another marijuana megadeal?

  • A Marijuana Mega-Merger Between Aurora Cannabis and MedReleaf Would Be a Bad Idea
    Motley Fool2 months ago

    A Marijuana Mega-Merger Between Aurora Cannabis and MedReleaf Would Be a Bad Idea

    Sometimes bigger isn't better.